Announcements of new AI deals, partnerships and product launches in biopharma are coming at a rapid pace. A new report from Research and Markets, AI In Pharma Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change, predicts this segment will grow from almost $699.3 million in 2020 to more than $2.895 billion in 2025.

Shares of Xencor were down nearly 6 percent after announcing Novartis terminated the company’s rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific, which was part of a 2016 collaboration valued at $2.6 billion.

Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.

Cambridge, Mass.-based Moderna and Emeryville, Calif.-based Metagenomi inked a strategic research and development deal on new gene editing systems for in vivo (in the body) human therapies.

Merck is widening the company’s reach into the treatment of autoimmune diseases by investing in Synthekine, a bioresearch company that develops engineered cytokine therapeutics. 

Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.

Four months after forging a collaboration to develop an experimental atopic dermatitis treatment, Amgen and Japan’s Kyowa Kirin are beginning to see the fruits of that deal with positive Phase II data for AMG 451/KHK4083, a potential first-in-class anti-OX40 monoclonal antibody.

Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.

GlaxoSmithKline said on Sept. 28 the company would develop an HIV treatment with Japan’s Shionogi for use in regimens with dosing gaps of three months or more, as the drugmaker seeks to build on the success of GSK’s previous long-acting therapies.

Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.